TransCode Therapeutics, Inc. (RNAZ) vs Beyond Air, Inc. (XAIR)

A side-by-side comparison of TransCode Therapeutics, Inc. and Beyond Air, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — RNAZ vs XAIR

growth of $100 · dividends reinvested · last 5y
RNAZ -100.0% (-94.2%/yr)XAIR -99.9% (-74.2%/yr)XAIR compounded faster over this window
Log scale — wide-divergence pair
000001101001kStart $10020222023202420252026$0$0
RNAZ XAIR

RNAZ vs XAIR: by the numbers

  • •XAIR is the larger company ($2M vs $2M market cap).
  • •Both run net losses; RNAZ's is the smaller (0.00% vs -435.71% net margin).

Metrics side by side

Valuation

MetricRNAZXAIR
P/S ratioN/A0.24

Profitability

MetricRNAZXAIR
Gross margin0.00%4.18%
Operating margin0.00%-378.23%
Net margin0.00%-435.71%
ROE-30.92%-1677.17%
ROIC-23.73%-106.06%

Growth (annualized)

MetricRNAZXAIR
Revenue CAGR (5Y)N/A64.21%
Total return CAGR (5Y)-93.39%-76.73%

Frequently asked

How have RNAZ and XAIR total returns compared?
Over the past 5 years, RNAZ delivered -93.39% and XAIR delivered -76.73% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.